Inclusion Criteria:

- Histologic diagnosis of adenocarcinoma of the prostate within six months of entry

- Clinical stage T1B, T1C, T2A-C NX MO (see Appendix 1 for staging). Any Gleason score
is eligible for entry, but Gleason score must be determined.

- Patients with a PSA >10.0 and Gleason score of 7; or patients with any PSA value and
Gleason score of >8 must have clinically negative lymph nodes as determined by a
pelvic CT scan done within 12 weeks of entry. A negative bone scan is required
before entry for all patients with Gleason score >8, or any patient with a Gleason
score of 7, and a PSA >10.

- The patient must not have received any cytotoxic anticancer therapy. Previous or
concurrent hormonal therapy for local disease is acceptable.

- ECOG performance status of 1 or less

- Age 80 years old or less

- Serum PSA <25 ng/ml within 4 weeks of study entry

- Informed consent

Exclusion Criteria:

- Patients with history of inflammatory bowel disease or other contraindication to
radical radiation therapy

- Patients with prior colorectal surgery

- Any prior pelvic radiotherapy. Any prior TURP done <12 weeks from study entry.

- Any previous cytotoxic chemotherapy

- Patients with prior malignancy except non-melanoma skin carcinoma within 5 years of
the diagnosis of prostate cancer